nach oben

CNS Drugs

Erschienen in:

01.05.2006 | Adis Drug Profile

Zolpidem Extended-Release

verfasst von: Marit D. Moen, Greg L. Plosker

Erschienen in: CNS Drugs | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

▲ Zolpidem extended-release, or controlled-release (CR), is a new formulation of zolpidem, a nonbenzodiazepine hypnotic. It is indicated in the US for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance. Zolpidem CR is a dual-layered tablet; one layer releases zolpidem immediately and a second layer provides a slower release of additional zolpidem for maintenance of plasma zolpidem concentrations.

▲ Efficacy of zolpidem CR was assessed in two 3-week, randomised, double-blind, placebo-controlled, phase III polysomnography trials in younger adult (aged 18–64 years) or elderly (aged ≥65 years) patients with primary insomnia. Patients received nightly zolpidem CR (12.5mg in younger adult and 6.25mg in elderly patients). Efficacy was assessed objectively on nights 1, 2, 15 and 16. Patients who received zolpidem CR had significantly improved objective latency to persistent sleep, wake time after sleep onset and sleep efficiency on assessment nights compared with placebo recipients.

▲ In subjective assessments of sleep quality on day 2 and nights 15 and 22, significantly more zolpidem CR than placebo recipients gave favourable responses on a Patient Global Impression scale in the study in younger adult patients. In the other study, significantly more elderly patients in the zolpidem CR group rated their sleep as improved compared with the placebo group.

▲ Zolpidem CR was generally well tolerated and appears to have a tolerability profile similar to that of the original formulation of zolpidem.

The use of trade names is for product identification purposes only and does not imply endorsement

National Institutes of Health. National Institutes of Health state of the science conference statement: manifestations and management of chronic insomnia in adults June 13–15, 2005. Sleep 2005 Sep 1; 28(9): 1049–57

Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004; 65 Suppl. 8: 13–9PubMed

Sanofi-Synthelabo Inc. Ambien® (zolpidem tartrate tablets): US prescribing information [online]. Available from URL: http://www.sanofi-aventis.us/ [Accessed 2006 Mar 14]

Swainston Harrison T, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 2005; 19(1): 65–89PubMedCrossRef

Sanofi-Synthelabo Inc. Ambien CR™ (zolpidem tartrate extended-release tablets): US prescribing information [online]. Available from URL: http://www.sanofi-aventis.us/ [Accessed 2005 Oct 14]

Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000 Apr; 59(4): 865–89PubMedCrossRef

Stanley N, Hindmarch I, Legangneux E, et al. Zolpidem modified-release 12.5 mg improves measures of sleep continuity in a model of sleep disturbance (traffic noise) compared with standard zolpidem 10 mg [abstract no. 321]. Pharmacotherapy 2005; 25(10): 1504. Plus oral presentation presented at the 2005 Annual Meeting of the American College of Clinical Pharmacy; 2005 Oct 23–26; San Francisco (CA)

Hindmarch I, Stanley N, Legangneux E, et al. Zolpidem modified-release significantly reduces latency to persistent sleep 4 and 5 hours postdose compared with standard zolpidem in a model assessing the return to sleep following nocturnal awakening [abstract no. 0731]. Sleep 2005; 28 Suppl.: A245. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18–23; Denver (CO)

Blin O, Micallef-Rolle J, Legangneux E, et al. Zolpidem modified-release 12.5 mg has no residual effects on psychomotor performance and cognitive function in healthy adult subjects [abstract no. 0733]. Sleep 2005; 28 Suppl.: A246. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18–23; Denver (CO)

10.

Legangneux E, Hindmarch I, Zobouyan I. Zolpidem modified-release 6.25 mg and double dose 12.5 mg have no residual effects on central nervous system integrative capacity, sensorimotor and psychomotor performance, and immediate and delayed memory recall in healthy elderly subjects [abstract no. 0729]. Sleep 2005; 28 Suppl.: A245. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18–23; Denver (CO)

11.

Soubrane C, Walsh J, Roth T. Zolpidem modified-release improves sleep induction, sleep maintenance, sleep duration, and quality of sleep without next-day residual effects in adults with primary insomnia [abstract no. 0728]. Sleep 2005; 28 Suppl.: A244–A245. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18–23; Denver (CO)

12.

Roehrs TA, Soubrane C, Roth T. Zolpidem modified-release objectively and subjectively improves sleep maintenance and retains the characteristics of standard zolpidem on sleep initiation and duration in elderly patients with primary insomnia [abstract no. 0725]. Sleep 2005; 28 Suppl.: A244. Plus poster presented at the 19th Annual Meeting of the Associated Professional Sleep Societies; 2005 Jun 18–23; Denver (CO)

13.

Johnston GA. GABAa receptor channel pharmacology. Curr Pharm Des 2005; 11(15): 1867–85PubMedCrossRef

14.

Data on file. Sanofi-Aventis, 2006

15.

Weinling E, McDougall S, Andre F, et al. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improved sleep maintenance. Fundam Clin Pharmacol 2006, doi: 10.1111/j.l472-8206.2006.00415.x

Titel: Zolpidem Extended-Release
verfasst von: Marit D. Moen
Greg L. Plosker
Publikationsdatum: 01.05.2006
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 5/2006
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200620050-00006

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2006

Role of Melatonin in the Pathophysiology of Migraine

Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia